Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis

July 24, 2026 06:34 AM EDT R&DPharma Sanofi nix­es Kymab-orig­i­nat­ed OX40L an­ti­body in eczema Elizabeth Cairns Senior biopharma journalist Sanofi has de­cid­ed to stop work­ing on a drug for eczema it had hoped would be a suc­ces­sor to its im­muno­log­i­cal mega-block­buster Dupix­ent. The French … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER